ID   PI51C_HUMAN             Reviewed;         668 AA.
AC   O60331; B7Z9E7; C6GIJ7; C6GIJ8; Q7LE07;
DT   25-OCT-2005, integrated into UniProtKB/Swiss-Prot.
DT   25-OCT-2005, sequence version 2.
DT   15-MAR-2017, entry version 140.
DE   RecName: Full=Phosphatidylinositol 4-phosphate 5-kinase type-1 gamma;
DE            Short=PIP5K1-gamma;
DE            Short=PtdIns(4)P-5-kinase 1 gamma;
DE            EC=2.7.1.68;
DE   AltName: Full=Phosphatidylinositol 4-phosphate 5-kinase type I gamma;
DE            Short=PIP5KIgamma;
GN   Name=PIP5K1C; Synonyms=KIAA0589;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 2 AND 3), SUBCELLULAR LOCATION,
RP   AND TISSUE SPECIFICITY.
RX   PubMed=19548880; DOI=10.1042/BJ20090638;
RA   Schill N.J., Anderson R.A.;
RT   "Two novel phosphatidylinositol-4-phosphate 5-kinase type Igamma
RT   splice variants expressed in human cells display distinctive cellular
RT   targeting.";
RL   Biochem. J. 422:473-482(2009).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Brain;
RX   PubMed=9628581; DOI=10.1093/dnares/5.1.31;
RA   Nagase T., Ishikawa K., Miyajima N., Tanaka A., Kotani H., Nomura N.,
RA   Ohara O.;
RT   "Prediction of the coding sequences of unidentified human genes. IX.
RT   The complete sequences of 100 new cDNA clones from brain which can
RT   code for large proteins in vitro.";
RL   DNA Res. 5:31-39(1998).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 4).
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15057824; DOI=10.1038/nature02399;
RA   Grimwood J., Gordon L.A., Olsen A.S., Terry A., Schmutz J.,
RA   Lamerdin J.E., Hellsten U., Goodstein D., Couronne O., Tran-Gyamfi M.,
RA   Aerts A., Altherr M., Ashworth L., Bajorek E., Black S., Branscomb E.,
RA   Caenepeel S., Carrano A.V., Caoile C., Chan Y.M., Christensen M.,
RA   Cleland C.A., Copeland A., Dalin E., Dehal P., Denys M., Detter J.C.,
RA   Escobar J., Flowers D., Fotopulos D., Garcia C., Georgescu A.M.,
RA   Glavina T., Gomez M., Gonzales E., Groza M., Hammon N., Hawkins T.,
RA   Haydu L., Ho I., Huang W., Israni S., Jett J., Kadner K., Kimball H.,
RA   Kobayashi A., Larionov V., Leem S.-H., Lopez F., Lou Y., Lowry S.,
RA   Malfatti S., Martinez D., McCready P.M., Medina C., Morgan J.,
RA   Nelson K., Nolan M., Ovcharenko I., Pitluck S., Pollard M.,
RA   Popkie A.P., Predki P., Quan G., Ramirez L., Rash S., Retterer J.,
RA   Rodriguez A., Rogers S., Salamov A., Salazar A., She X., Smith D.,
RA   Slezak T., Solovyev V., Thayer N., Tice H., Tsai M., Ustaszewska A.,
RA   Vo N., Wagner M., Wheeler J., Wu K., Xie G., Yang J., Dubchak I.,
RA   Furey T.S., DeJong P., Dickson M., Gordon D., Eichler E.E.,
RA   Pennacchio L.A., Richardson P., Stubbs L., Rokhsar D.S., Myers R.M.,
RA   Rubin E.M., Lucas S.M.;
RT   "The DNA sequence and biology of human chromosome 19.";
RL   Nature 428:529-535(2004).
RN   [5]
RP   FUNCTION, INTERACTION WITH TLN2, SUBCELLULAR LOCATION, AND ENZYME
RP   REGULATION.
RX   PubMed=12422219; DOI=10.1038/nature01147;
RA   Di Paolo G., Pellegrini L., Letinic K., Cestra G., Zoncu R.,
RA   Voronov S., Chang S., Guo J., Wenk M.R., De Camilli P.;
RT   "Recruitment and regulation of phosphatidylinositol phosphate kinase
RT   type 1 gamma by the FERM domain of talin.";
RL   Nature 420:85-89(2002).
RN   [6]
RP   FUNCTION, INTERACTION WITH ARF6, AND SUBCELLULAR LOCATION.
RX   PubMed=12847086; DOI=10.1083/jcb.200301006;
RA   Krauss M., Kinuta M., Wenk M.R., De Camilli P., Takei K., Haucke V.;
RT   "ARF6 stimulates clathrin/AP-2 recruitment to synaptic membranes by
RT   activating phosphatidylinositol phosphate kinase type Igamma.";
RL   J. Cell Biol. 162:113-124(2003).
RN   [7]
RP   PHOSPHORYLATION AT TYR-649 AND SER-650, AND MUTAGENESIS OF SER-650.
RX   PubMed=15738269; DOI=10.1083/jcb.200409028;
RA   Lee S.Y., Voronov S., Letinic K., Nairn A.C., Di Paolo G.,
RA   De Camilli P.;
RT   "Regulation of the interaction between PIPKI gamma and talin by
RT   proline-directed protein kinases.";
RL   J. Cell Biol. 168:789-799(2005).
RN   [8]
RP   FUNCTION, SUBCELLULAR LOCATION, AND INTERACTION WITH CDH1.
RX   PubMed=17261850; DOI=10.1083/jcb.200606023;
RA   Ling K., Bairstow S.F., Carbonara C., Turbin D.A., Huntsman D.G.,
RA   Anderson R.A.;
RT   "Type I gamma phosphatidylinositol phosphate kinase modulates adherens
RT   junction and E-cadherin trafficking via a direct interaction with mu
RT   1B adaptin.";
RL   J. Cell Biol. 176:343-353(2007).
RN   [9]
RP   FUNCTION IN CELL MIGRATION AND ADHESION.
RX   PubMed=17635937; DOI=10.1083/jcb.200701078;
RA   Sun Y., Ling K., Wagoner M.P., Anderson R.A.;
RT   "Type I gamma phosphatidylinositol phosphate kinase is required for
RT   EGF-stimulated directional cell migration.";
RL   J. Cell Biol. 178:297-308(2007).
RN   [10]
RP   ACETYLATION AT LYS-265 AND LYS-268, AND DEACETYLATION BY SIRT1.
RX   PubMed=20668706; DOI=10.1371/journal.pone.0011755;
RA   Akieda-Asai S., Zaima N., Ikegami K., Kahyo T., Yao I., Hatanaka T.,
RA   Iemura S., Sugiyama R., Yokozeki T., Eishi Y., Koike M., Ikeda K.,
RA   Chiba T., Yamaza H., Shimokawa I., Song S.Y., Matsuno A., Mizutani A.,
RA   Sawabe M., Chao M.V., Tanaka M., Kanaho Y., Natsume T., Sugimura H.,
RA   Date Y., McBurney M.W., Guarente L., Setou M.;
RT   "SIRT1 regulates thyroid-stimulating hormone release by enhancing
RT   PIP5Kgamma activity through deacetylation of specific lysine residues
RT   in mammals.";
RL   PLoS ONE 5:E11755-E11755(2010).
RN   [11]
RP   REVIEW ON FUNCTION.
RX   PubMed=19889969; DOI=10.1242/jcs.056127;
RA   van den Bout I., Divecha N.;
RT   "PIP5K-driven PtdIns(4,5)P2 synthesis: regulation and cellular
RT   functions.";
RL   J. Cell Sci. 122:3837-3850(2009).
RN   [12]
RP   VARIANT LCCS3 ASN-253, AND CHARACTERIZATION OF VARIANT LCCS3 ASN-253.
RX   PubMed=17701898; DOI=10.1086/520771;
RA   Narkis G., Ofir R., Landau D., Manor E., Volokita M., Hershkowitz R.,
RA   Elbedour K., Birk O.S.;
RT   "Lethal contractural syndrome type 3 (LCCS3) is caused by a mutation
RT   in PIP5K1C, which encodes PIPKI gamma of the phophatidylinositol
RT   pathway.";
RL   Am. J. Hum. Genet. 81:530-539(2007).
CC   -!- FUNCTION: Catalyzes the phosphorylation of phosphatidylinositol 4-
CC       phosphate (PtdIns4P) to form phosphatidylinositol 4,5-bisphosphate
CC       (PtdIns(4,5)P2). PtdIns(4,5)P2 is involved in a variety of
CC       cellular processes and is the substrate to form
CC       phosphatidylinositol 3,4,5-trisphosphate (PtdIns(3,4,5)P3),
CC       another second messenger. The majority of PtdIns(4,5)P2 is thought
CC       to occur via type I phosphatidylinositol 4-phosphate 5-kinases
CC       given the abundance of PtdIns4P. Participates in a variety of
CC       cellular processes such as vesicle mediated transport, cell
CC       adhesion, cell polarization and cell migration. Together with
CC       PIP5K1A is required for phagocytosis, but they regulate different
CC       types of actin remodeling at sequential steps. Promotes particle
CC       attachment by generating the pool of PtdIns(4,5)P2 that induces
CC       controlled actin depolymerization to facilitate Fc-gamma-R
CC       clustering. Mediates RAC1-dependent reorganization of actin
CC       filaments. Required for synaptic vesicle transport. Controls the
CC       plasma membrane pool of PtdIns(4,5)P2 implicated in synaptic
CC       vesicle endocytosis and exocytosis. Plays a role in endocytosis
CC       mediated by clathrin and AP-2 (adaptor protein complex 2).
CC       Required for clathrin-coated pits assembly at the synapse.
CC       Participates in cell junction assembly. Modulates adherens
CC       junctions formation by facilitating CDH1 trafficking. Required for
CC       focal adhesion dynamics. Modulates the targeting of talins (TLN1
CC       and TLN2) to the plasma membrane and their efficient assembly into
CC       focal adhesions. Regulates the interaction between talins (TLN1
CC       and TLN2) and beta-integrins. Required for uropodium formation and
CC       retraction of the cell rear during directed migration. Has a role
CC       in growth factor- stimulated directional cell migration and
CC       adhesion. Required for talin assembly into nascent adhesions
CC       forming at the leading edge toward the direction of the growth
CC       factor. Negative regulator of T-cell activation and adhesion.
CC       Negatively regulates integrin alpha-L/beta-2 (LFA-1) polarization
CC       and adhesion induced by T-cell receptor. Together with PIP5K1A
CC       have a role during embryogenesis and together with PIP5K1B may
CC       have a role immediately after birth. {ECO:0000269|PubMed:12422219,
CC       ECO:0000269|PubMed:12847086, ECO:0000269|PubMed:17261850,
CC       ECO:0000269|PubMed:17635937}.
CC   -!- CATALYTIC ACTIVITY: ATP + 1-phosphatidyl-1D-myo-inositol 4-
CC       phosphate = ADP + 1-phosphatidyl-1D-myo-inositol 4,5-bisphosphate.
CC   -!- ENZYME REGULATION: Activated by interaction with TLN2.
CC       {ECO:0000269|PubMed:12422219}.
CC   -!- SUBUNIT: Interacts with TLN1 (By similarity). Interacts with TLN2;
CC       interaction stimulates lipid kinase activity. May compete with
CC       beta-integrins for the same binding site on TLN1 and TLN2.
CC       Interacts with ARF6. Interacts with AP2B1. Interacts with AP2M1;
CC       phosphorylation of PIP5K1C by CSK disrupts the interaction;
CC       clathrin competes with PIP5K1C (By similarity). Interacts with
CC       CDH1. Interacts with CSK (By similarity). Interacts with PLCG1;
CC       interaction is abolished upon EGF stimulation (By similarity).
CC       {ECO:0000250}.
CC   -!- INTERACTION:
CC       P46940:IQGAP1; NbExp=6; IntAct=EBI-8838062, EBI-297509;
CC   -!- SUBCELLULAR LOCATION: Cell membrane; Peripheral membrane protein;
CC       Cytoplasmic side. Endomembrane system. Cytoplasm. Cell junction,
CC       focal adhesion. Cell junction, adherens junction. Cell projection,
CC       ruffle membrane. Cell projection, phagocytic cup. Cell projection,
CC       uropodium. Note=Detected in plasma membrane invaginations. Isoform
CC       3 is detected in intracellular vesicle-like structures.
CC   -!- SUBCELLULAR LOCATION: Isoform 2: Cytoplasm. Nucleus.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=4;
CC       Name=1; Synonyms=PIPKIgamma-90, PIPKIgamma-668, PIPkinIgamma-a,
CC       PIPKIgamma_i2;
CC         IsoId=O60331-1; Sequence=Displayed;
CC       Name=2; Synonyms=variant 700, PIPKIgamma-700, PIPKIgamma_i4;
CC         IsoId=O60331-2; Sequence=VSP_042078;
CC       Name=3; Synonyms=variant 707, PIPKIgamma-707, PIPKIgamma_i5;
CC         IsoId=O60331-3; Sequence=VSP_042080;
CC       Name=4; Synonyms=PIPKIgamma-87, PIPKIgamma-640, PIPkinIgamma-b,
CC       PIPKIgamma_i1;
CC         IsoId=O60331-4; Sequence=VSP_042079;
CC   -!- TISSUE SPECIFICITY: Isoform 1 is strongly expressed in brain and
CC       also detected in heart and lung. Isoform 2 is strongly expressed
CC       in pancreas and liver and in lesser quantities in brain, heart,
CC       lung and kidney. Isoform 3 is detected in large amounts in heart
CC       and large intestine, is also present in lung, pancreas and
CC       thyroid, and to a lesser extent in brain, stomach and kidney.
CC       {ECO:0000269|PubMed:19548880}.
CC   -!- PTM: Phosphorylation on Ser-650 negatively regulates binding to
CC       TLN2 and is strongly stimulated in mitosis. Phosphorylation on
CC       Tyr-649 is necessary for targeting to focal adhesions.
CC       Phosphorylation on Ser-650 and Tyr-649 are mutually exclusive.
CC       Phosphorylated by SYK and CSK (By similarity). Tyrosine
CC       phosphorylation is enhanced by PTK2 signaling. Phosphorylated at
CC       Tyr-639 upon EGF stimulation. Some studies suggest that
CC       phosphorylation on Tyr-649 enhances binding to tailins (TLN1 and
CC       TLN2). According to PubMed:15738269 phosphorylation at Tyr-649
CC       does not directly enhance binding to tailins (TLN1 and TLN2) but
CC       may act indirectly by inhibiting phosphorylation at Ser-650.
CC       {ECO:0000250, ECO:0000269|PubMed:15738269}.
CC   -!- PTM: Acetylation at Lys-265 and Lys-268 seems to decrease lipid
CC       kinase activity. Deacetylation of these sites by SIRT1 positively
CC       regulates the exocytosis of TSH-containing granules from pituitary
CC       cells. {ECO:0000269|PubMed:20668706}.
CC   -!- DISEASE: Lethal congenital contracture syndrome 3 (LCCS3)
CC       [MIM:611369]: A form of lethal congenital contracture syndrome, an
CC       autosomal recessive disorder characterized by degeneration of
CC       anterior horn neurons, extreme skeletal muscle atrophy, and
CC       congenital non-progressive joint contractures (arthrogryposis).
CC       The contractures can involve the upper or lower limbs and/or the
CC       vertebral column, leading to various degrees of flexion or
CC       extension limitations evident at birth. LCCS3 patients present at
CC       birth with severe multiple joint contractures and severe muscle
CC       wasting and atrophy, mainly in the legs. Death occurs minutes to
CC       hours after birth due to respiratory insufficiency. The phenotype
CC       can be distinguished from that of LCCS1 by the absence of hydrops,
CC       fractures and multiple pterygia, and from LCCS2 by the absence of
CC       neurogenic bladder defect. {ECO:0000269|PubMed:17701898}. Note=The
CC       disease is caused by mutations affecting the gene represented in
CC       this entry.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=BAA25515.1; Type=Erroneous initiation; Note=Translation N-terminally shortened.; Evidence={ECO:0000305};
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; FJ965536; ACS73483.1; -; mRNA.
DR   EMBL; FJ965537; ACS73484.1; -; mRNA.
DR   EMBL; AB011161; BAA25515.1; ALT_INIT; mRNA.
DR   EMBL; AK315912; BAH14283.1; -; mRNA.
DR   EMBL; AC005542; AAC32904.1; -; Genomic_DNA.
DR   EMBL; AC093071; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC004637; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   CCDS; CCDS32872.1; -. [O60331-1]
DR   CCDS; CCDS56074.1; -. [O60331-4]
DR   CCDS; CCDS74257.1; -. [O60331-3]
DR   RefSeq; NP_001182662.1; NM_001195733.1. [O60331-4]
DR   RefSeq; NP_001287778.1; NM_001300849.1. [O60331-3]
DR   RefSeq; NP_036530.1; NM_012398.2. [O60331-1]
DR   UniGene; Hs.282177; -.
DR   PDB; 2G35; NMR; -; B=646-653.
DR   PDB; 3H1Z; X-ray; 1.83 A; P=639-653.
DR   PDB; 3H85; X-ray; 2.60 A; P=646-653.
DR   PDBsum; 2G35; -.
DR   PDBsum; 3H1Z; -.
DR   PDBsum; 3H85; -.
DR   ProteinModelPortal; O60331; -.
DR   SMR; O60331; -.
DR   BioGrid; 116969; 12.
DR   DIP; DIP-39809N; -.
DR   IntAct; O60331; 1.
DR   STRING; 9606.ENSP00000335333; -.
DR   BindingDB; O60331; -.
DR   ChEMBL; CHEMBL1908383; -.
DR   GuidetoPHARMACOLOGY; 2165; -.
DR   SwissLipids; SLP:000000551; -. [O60331-4]
DR   iPTMnet; O60331; -.
DR   PhosphoSitePlus; O60331; -.
DR   SwissPalm; O60331; -.
DR   BioMuta; PIP5K1C; -.
DR   EPD; O60331; -.
DR   MaxQB; O60331; -.
DR   PaxDb; O60331; -.
DR   PeptideAtlas; O60331; -.
DR   PRIDE; O60331; -.
DR   DNASU; 23396; -.
DR   Ensembl; ENST00000335312; ENSP00000335333; ENSG00000186111. [O60331-1]
DR   Ensembl; ENST00000537021; ENSP00000444779; ENSG00000186111. [O60331-2]
DR   Ensembl; ENST00000539785; ENSP00000445992; ENSG00000186111. [O60331-4]
DR   Ensembl; ENST00000589578; ENSP00000466363; ENSG00000186111. [O60331-3]
DR   GeneID; 23396; -.
DR   KEGG; hsa:23396; -.
DR   UCSC; uc002lyj.3; human. [O60331-1]
DR   CTD; 23396; -.
DR   DisGeNET; 23396; -.
DR   GeneCards; PIP5K1C; -.
DR   HGNC; HGNC:8996; PIP5K1C.
DR   HPA; HPA017168; -.
DR   MalaCards; PIP5K1C; -.
DR   MIM; 606102; gene.
DR   MIM; 611369; phenotype.
DR   neXtProt; NX_O60331; -.
DR   OpenTargets; ENSG00000186111; -.
DR   Orphanet; 137783; Lethal congenital contracture syndrome type 3.
DR   PharmGKB; PA33329; -.
DR   eggNOG; KOG0229; Eukaryota.
DR   eggNOG; COG5253; LUCA.
DR   GeneTree; ENSGT00760000119184; -.
DR   HOGENOM; HOG000193876; -.
DR   HOVERGEN; HBG052818; -.
DR   InParanoid; O60331; -.
DR   KO; K00889; -.
DR   OMA; PTDERSW; -.
DR   OrthoDB; EOG091G0A6L; -.
DR   PhylomeDB; O60331; -.
DR   TreeFam; TF319618; -.
DR   BioCyc; MetaCyc:HS02710-MONOMER; -.
DR   Reactome; R-HSA-1660499; Synthesis of PIPs at the plasma membrane.
DR   Reactome; R-HSA-399955; SEMA3A-Plexin repulsion signaling by inhibiting Integrin adhesion.
DR   Reactome; R-HSA-6811558; PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling.
DR   Reactome; R-HSA-8856828; Clathrin-mediated endocytosis.
DR   SIGNOR; O60331; -.
DR   ChiTaRS; PIP5K1C; human.
DR   EvolutionaryTrace; O60331; -.
DR   GeneWiki; PIP5K1C; -.
DR   GenomeRNAi; 23396; -.
DR   PRO; PR:O60331; -.
DR   Proteomes; UP000005640; Chromosome 19.
DR   Bgee; ENSG00000186111; -.
DR   CleanEx; HS_PIP5K1C; -.
DR   Genevisible; O60331; HS.
DR   GO; GO:0005829; C:cytosol; IDA:HPA.
DR   GO; GO:0012505; C:endomembrane system; IEA:UniProtKB-SubCell.
DR   GO; GO:0005925; C:focal adhesion; TAS:UniProtKB.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0001891; C:phagocytic cup; IEA:UniProtKB-SubCell.
DR   GO; GO:0098793; C:presynapse; IEA:GOC.
DR   GO; GO:0032587; C:ruffle membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0001931; C:uropod; TAS:UniProtKB.
DR   GO; GO:0052811; F:1-phosphatidylinositol-3-phosphate 4-kinase activity; TAS:Reactome.
DR   GO; GO:0016308; F:1-phosphatidylinositol-4-phosphate 5-kinase activity; TAS:Reactome.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0052812; F:phosphatidylinositol-3,4-bisphosphate 5-kinase activity; TAS:Reactome.
DR   GO; GO:0030036; P:actin cytoskeleton organization; TAS:UniProtKB.
DR   GO; GO:0034333; P:adherens junction assembly; TAS:UniProtKB.
DR   GO; GO:0072583; P:clathrin-dependent endocytosis; TAS:UniProtKB.
DR   GO; GO:0061024; P:membrane organization; TAS:Reactome.
DR   GO; GO:0030593; P:neutrophil chemotaxis; TAS:UniProtKB.
DR   GO; GO:0006909; P:phagocytosis; TAS:UniProtKB.
DR   GO; GO:0006661; P:phosphatidylinositol biosynthetic process; TAS:Reactome.
DR   GO; GO:0014066; P:regulation of phosphatidylinositol 3-kinase signaling; TAS:Reactome.
DR   GO; GO:0016337; P:single organismal cell-cell adhesion; TAS:UniProtKB.
DR   GO; GO:0048488; P:synaptic vesicle endocytosis; TAS:UniProtKB.
DR   GO; GO:0016079; P:synaptic vesicle exocytosis; TAS:UniProtKB.
DR   Gene3D; 3.30.800.10; -; 1.
DR   Gene3D; 3.30.810.10; -; 1.
DR   InterPro; IPR023610; PInositol-4-P-5-kinase.
DR   InterPro; IPR027483; PInositol-4-P-5-kinase_C.
DR   InterPro; IPR002498; PInositol-4-P-5-kinase_core.
DR   InterPro; IPR027484; PInositol-4-P-5-kinase_N.
DR   PANTHER; PTHR23086; PTHR23086; 1.
DR   Pfam; PF01504; PIP5K; 1.
DR   SMART; SM00330; PIPKc; 1.
DR   PROSITE; PS51455; PIPK; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Alternative splicing; ATP-binding;
KW   Cell adhesion; Cell junction; Cell membrane; Cell projection;
KW   Chemotaxis; Complete proteome; Cytoplasm; Disease mutation;
KW   Endocytosis; Exocytosis; Kinase; Membrane; Methylation;
KW   Nucleotide-binding; Nucleus; Phagocytosis; Phosphoprotein;
KW   Reference proteome; Transferase.
FT   CHAIN         1    668       Phosphatidylinositol 4-phosphate 5-kinase
FT                                type-1 gamma.
FT                                /FTId=PRO_0000185462.
FT   DOMAIN       75    443       PIPK. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00781}.
FT   REGION      641    668       Mediates interaction with TLN2.
FT                                {ECO:0000269|PubMed:12422219}.
FT   MOD_RES     265    265       N6-acetyllysine.
FT                                {ECO:0000269|PubMed:20668706}.
FT   MOD_RES     268    268       N6-acetyllysine.
FT                                {ECO:0000269|PubMed:20668706}.
FT   MOD_RES     459    459       Asymmetric dimethylarginine; alternate.
FT                                {ECO:0000250|UniProtKB:O70161}.
FT   MOD_RES     459    459       Omega-N-methylarginine; alternate.
FT                                {ECO:0000250|UniProtKB:O70161}.
FT   MOD_RES     555    555       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q5I6B8}.
FT   MOD_RES     639    639       Phosphotyrosine; by EGFR. {ECO:0000250}.
FT   MOD_RES     649    649       Phosphotyrosine; by CSK.
FT                                {ECO:0000269|PubMed:15738269}.
FT   MOD_RES     650    650       Phosphoserine; by CDK5, MAPK1 and CDK1.
FT                                {ECO:0000269|PubMed:15738269}.
FT   MOD_RES     662    662       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:O70161}.
FT   MOD_RES     666    666       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q5I6B8}.
FT   MOD_RES     668    668       Phosphothreonine.
FT                                {ECO:0000250|UniProtKB:Q5I6B8}.
FT   VAR_SEQ     640    668       FPTDERSWVYSPLHYSAQAPPASDGESDT -> FWRLWGPH
FT                                APTWPWRREGRAACLCPYPPHVVTPFPGTGLCASWSPDGTG
FT                                GLGAMSCCVSVS (in isoform 2).
FT                                {ECO:0000303|PubMed:19548880}.
FT                                /FTId=VSP_042078.
FT   VAR_SEQ     641    668       PTDERSWVYSPLHYSAQAPPASDGESDT -> FTDGRYWIY
FT                                SPRHRRLRAVTLSASGTVSDRSRPPWGEGAVPLGQQGAAGP
FT                                RPEAQCLTSVVFQKGFG (in isoform 3).
FT                                {ECO:0000303|PubMed:19548880}.
FT                                /FTId=VSP_042080.
FT   VAR_SEQ     641    668       Missing (in isoform 4).
FT                                {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_042079.
FT   VARIANT     253    253       D -> N (in LCCS3; loss of activity;
FT                                dbSNP:rs121908315).
FT                                {ECO:0000269|PubMed:17701898}.
FT                                /FTId=VAR_036996.
FT   MUTAGEN     650    650       S->D: Abolishes binding to TLN2. Affects
FT                                localization to focal adhesions.
FT                                {ECO:0000269|PubMed:15738269}.
FT   MUTAGEN     650    650       S->N: Does not affect binding to TLN2 and
FT                                localization to focal adhesions.
FT                                {ECO:0000269|PubMed:15738269}.
FT   CONFLICT    236    236       V -> M (in Ref. 3; BAH14283).
FT                                {ECO:0000305}.
FT   HELIX       644    646       {ECO:0000244|PDB:3H1Z}.
SQ   SEQUENCE   668 AA;  73260 MW;  45A9FB32B4E43083 CRC64;
     MELEVPDEAE SAEAGAVPSE AAWAAESGAA AGLAQKKAAP TEVLSMTAQP GPGHGKKLGH
     RGVDASGETT YKKTTSSTLK GAIQLGIGYT VGHLSSKPER DVLMQDFYVV ESIFFPSEGS
     NLTPAHHFQD FRFKTYAPVA FRYFRELFGI RPDDYLYSLC NEPLIELSNP GASGSLFYVT
     SDDEFIIKTV MHKEAEFLQK LLPGYYMNLN QNPRTLLPKF YGLYCVQSGG KNIRVVVMNN
     ILPRVVKMHL KFDLKGSTYK RRASKKEKEK SFPTYKDLDF MQDMPEGLLL DADTFSALVK
     TLQRDCLVLE SFKIMDYSLL LGVHNIDQHE RERQAQGAQS TSDEKRPVGQ KALYSTAMES
     IQGGAARGEA IESDDTMGGI PAVNGRGERL LLHIGIIDIL QSYRFIKKLE HTWKALVHDG
     DTVSVHRPSF YAERFFKFMS NTVFRKNSSL KSSPSKKGRG GALLAVKPLG PTAAFSASQI
     PSEREEAQYD LRGARSYPTL EDEGRPDLLP CTPPSFEEAT TASIATTLSS TSLSIPERSP
     SETSEQPRYR RRTQSSGQDG RPQEEPPAEE DLQQITVQVE PACSVEIVVP KEEDAGVEAS
     PAGASAAVEV ETASQASDEE GAPASQASDE EDAPATDIYF PTDERSWVYS PLHYSAQAPP
     ASDGESDT
//
